

Special Issue

Biomarkers for Gynecological Cancers

Message from the Guest Editor

Gynecological cancers, such as cervical, ovarian, and endometrial cancers, pose significant challenges in early detection and treatment. Biomarkers, as biomolecules that can predict or indicate the risk, presence, or absence of a biological event, have emerged as a potential tool to indicate disease risk, presence, progression, response to therapy, and patient outcomes. Thus, identifications of reliable biomarkers in gynecological cancers are essential for improving their early and accurate detection, personalizing treatment regimens, and improving survival outcomes. These biomarkers could originate from the tumor tissues, whole body, or body fluid, including blood, urine, stool, and saliva. Such biomarkers could offer insights to guide clinical decisions and improve patient outcomes. However, high accuracy in the detection of biomarkers and the standardization of tests and the interpretation of their results is crucial to integrating them into routine clinical practice in order to enhance the precision of cancer detection and treatment.

Guest Editor

Dr. Apriliana Kartikasari

School of Health and Biomedical Sciences, RMIT University, Melbourne, VIC 3083, Australia

Deadline for manuscript submissions

closed (31 March 2026)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/220746

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)